Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00064
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
KGFRWR
|
|||||
| Structure |
|
|||||
| Sequence |
KGFRWR
|
|||||
| Peptide Type |
Linear
|
|||||
| PDC Transmembrane Types | Cell-penetrating peptides (CPPs) | |||||
| Formula |
C40H60N14O7
|
|||||
| Isosmiles |
[H]NCCCC[C@H](N[H])C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](Cc1cn([H])c2ccccc12)C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)O
|
|||||
| InChI |
InChI=1S/C40H60N14O7/c41-17-7-6-13-27(42)34(56)50-23-33(55)51-31(20-24-10-2-1-3-11-24)36(58)52-29(15-8-18-47-39(43)44)35(57)54-32(21-25-22-49-28-14-5-4-12-26(25)28)37(59)53-30(38(60)61)16-9-19-48-40(45)46/h1-5,10-12,14,22,27,29-32,49H,6-9,13,15-21,23,41-42H2,(H,50,56)(H,51,55)(H,52,58)(H,53,59)(H,54,57)(H,60,61)(H4,43,44,47)(H4,45,46,48)/t27-,29-,30-,31-,32-/m0/s1
|
|||||
| InChIKey |
XJDKSQWPJKYMHZ-QDNWXXHKSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
849.011
|
Polar area
|
379.43
|
||
|
Complexity
|
848.4769403
|
xlogp Value
|
-2.3434
|
|||
|
Heavy Count
|
61
|
Rot Bonds
|
29
|
|||
|
Hbond acc
|
10
|
Hbond Donor
|
13
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
DOXKGFRWR [Investigative]
Obtained from the Model Organism Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Hepatocellular carcinoma | ||||
| Efficacy Data | Tumor volume |
376 mm3
|
|||
| Description |
The antitumor efficacy of the DOX-KGFRWR nanofiber was superior to all other treatments, with a final tumor volume of 376 mm3.
|
||||
| In Vivo Model | SMMC7721 tumorbearing mice. | ||||
| Half life period | 24.52±13.17 h | ||||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Hepatocellular carcinoma | ||||
| Efficacy Data | Percent survival |
50%
|
|||
| Administration Time | 40 days | ||||
| Description |
DOX-KGFRWR has significantly prolonged survival rates.
|
||||
| In Vivo Model | SMMC7721 tumorbearing mice. | ||||
| Half life period | 24.52±13.17 h | ||||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Hepatocellular carcinoma | ||||
| Efficacy Data | Percent survival | > 40 days | |||
| Administration Time | 30 days | ||||
| Description |
DOX-KGFRWR has significantly prolonged survival rates.
|
||||
| In Vivo Model | SMMC7721 tumorbearing mice. | ||||
| Half life period | 24.52±13.17 h | ||||
| Experiment 4 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Hepatocellular carcinoma | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.27 µM
|
|||
| Description |
The IC50 values for KGFRWR, DOX, and DOX-KGFRWR against the MMP2 enzyme were 14.19, 8.68, and 5.27 10-6 m, respectively.
|
||||
| In Vivo Model | SMMC7721 pulmonary metastatic mouse model. | ||||
| Half life period | 24.52±13.17 h | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Hepatocellular carcinoma | ||||
| Efficacy Data | Migration rates |
19.90%
|
|||
| Description |
Cells treated with DOX and DOX-KGFRWR exhibited markedly decreased migration, with migration rates of 39.4% and 19.9%, respectively, compared with those in the control, indicating that DOX-KGWRFR exerted a stronger inhibiting effect on migration than DOX.
|
||||
| In Vitro Model | Hepatocellular carcinoma | SMMC-7721 cell | CVCL_0534 | ||
| Half life period | 24.52±13.17 h | ||||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Hepatocellular carcinoma | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
34.55 µg mL-1
|
|||
| Evaluation Method | MTT assay | ||||
| Description |
The IC50 values for DOX-KGFRWR is 34.55 μg mL-1.
|
||||
| In Vitro Model | Hepatocellular carcinoma | SMMC-7721 cell | CVCL_0534 | ||
| Half life period | 24.52±13.17 h | ||||
References